Scottsmyname, I am not a neuroscientist, and even I would be, in...

Scottsmyname, I am not a neuroscientist, and even I would be, in fact nobody knows if in the end the results in 201 or 202 are so good that FDA will approve 434 to the market for MSA patients. Prof. Claassen is a neuroscientist (172 publications in PubMed) but Stamler is not (26 papers, mostly written by others, I think). Neither of them invented ATH434 molecule. It was invented years earlier Stamler started in Prana. I do not think either of them are real business people but Stamler has conducted earlier a study resulting FDA approval and so conducting the 201 study he is the right person. It has been a huge study with a big number of sites round the world. You need to be a special person to get it planned and executed. The business skills needed to make a deal with Big Pharma are sitting in the board of ATH. But most likely external consults will be needed.

However, ATH has now, IMO, good possibilities to be successful according the 202 results we have today and according also many scientific papers. Iteresting to see if the meeting papers in this autumn will give stronger evidence together with 9 month follow-up of 202.